FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and immunology, specifically to nanoantibodies in monomeric and homodimeric forms, specifically binding and neutralizing TcdA, methods of producing said antibodies. Invention and/or any preparations and derivatives thereof can be used to eliminate and/or prevent the pathogenic effect of TcdA on the body in case of toxinemia which can be caused by C. difficile.
EFFECT: nanoantibodies of the present invention have pronounced toxin-neutralizing activity, which has been confirmed in in vitro and in vivo studies.
3 cl, 3 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS RELATED TO CLOSTRIDIUM DIFFICILE MUTANT TOXIN, AND METHODS OF APPLICATION THEREOF | 2012 |
|
RU2592686C2 |
| COMPOSITIONS AND METHODS RELEVANT TO MUTANT TOXIN FROM CLOSTRIDIUM DIFFICILE | 2013 |
|
RU2630671C2 |
| ANTI-POISONING MEDICATION | 2007 |
|
RU2465893C2 |
| ANTIBODIES FOR TREATMENT OF INFECTION AND DISEASES ASSOCIATED WITH CLOSTRIDIUM DIFFICILE | 2011 |
|
RU2630663C9 |
| SINGLE-DOMAIN NANO-ANTIBODIES AGAINST SPIKE PROTEIN OF SARS-CoV-2 VIRUS | 2021 |
|
RU2794141C2 |
| HUMAN ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS | 2013 |
|
RU2628305C2 |
| NANOANTIBODIES aMh1, aMh2 BINDING ANTIGEN OF MYCOPLASMA HOMINTS, METHOD OF PRODUCING THEM, METHOD OF TREATING MYCOPLASMA HOMINIS INFECTION | 2011 |
|
RU2484095C1 |
| MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
| HUMAN GENETIC MARKERS ASSOCIATED WITH RESPONSE TO TREATMENT AGENTS THAT TARGET TOXIN B CLOSTRIDIUM DIFFICILE | 2017 |
|
RU2761249C2 |
| NANOANTIBODIES BINDING CHLAMYDIA TRACHOMATIS ANTIGEN, METHOD OF INHIBITING INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS | 2012 |
|
RU2487724C1 |
